Effect of Hydroxychloroquine on Clinical Improvement and Mortality Among Patients with COVID-19 Admitted to Four General Hospitals in Saudi Arabia

Mohammed Alghamdi¹-*, Nasser Aljuhani², Afrah AL-Somali³, Saeed Alzahrani⁴, Rashed Aloitaibi⁵, Salma Siddiqua⁶, Marwah Naitah⁷, Sayda albelewi⁸, Ahmed Alghamdi⁹, Fayez Alotaibi¹⁰, Abdullmoin AlQarni¹¹, Khalid Al-Hariqi¹², Manal Al -Gethamy¹³

¹Infectious disease consultant, King Fahad General Hospital
²Nasser Rajallah Aljuhani, internal medicine and endocrinology Consultant, East Jeddah hospital
³Afrah A. AL-Somali, Infectious Diseases Department, King Abdullah medical complex, Jeddah, Saudi Arabia
⁴Saeed Alzahrani, Consultant Neurologist, King Fahd General Hospital, Jeddah, Saudi Arabia
⁵Rashed Hujeel Aloitaibi, Internal Medicine resident, King Fahd General Hospital, Jeddah, Saudi Arabia
⁶Salma Siddiqua, ENT, general physician, Saudi German Hospital, Jeddah, Saudi Arabia.
⁷Marwah Tariq Naitah, Medical specialist, Internal medicine, King Fahad general Hospital, Jeddah, Saudi Arabia.
⁸Sayda Hamed albelewi, internal medicine S.registrar, East jeddah hospital, Jeddah, Saudi Arabia.
⁹Ahmed Mashhour Alghamdi, Internal Medicine Resident, East Jeddah Hospital, Jeddah, Saudi Arabia.
¹⁰Fayez Omear Alotaibi, Director of pharmacy, Pharmacy, King Fahd general Hospital, Jeddah, Saudi Arabia.
¹¹Abdullmoin Mohammed AlQarni, Infectious Diseases- Internal Medicine Consultant, Alnoor Specialist Hospital, Makkah, Saudi Arabia.
¹²Khalid Waleed Abdullah Al-Hariqi, Internal Medicine Resident, Alnoor Specialist Hospital, Makkah, Saudi Arabia.
¹³Manal Mansour Mezal Al -Gethamy, Infectious Diseases-Internal Medicine Consultant, Department of Infection Prevention & Control, Alnoor Specialist Hospital, Makkah, Saudi Arabia.

Abstract
Background: The use of hydroxychloroquine in coronavirus disease (COVID-19) pandemic raised significant concerns as regards safety and efficacy in hospitalized patients. The objective was to examine the effect of hydroxychloroquine on clinical improvement and mortality among hospitalized patients with COVID-19.

Methods: A prospective cohort study was conducted at four general hospitals in the Western region, Saudi Arabia. Patients who had absolute or relative contraindication for using hydroxychloroquine were excluded. Patients concomitantly receiving other medications including azithromycin, antivirals, and supportive treatment were not excluded.

Results: A total 267 patients were included in the current analysis; 185 (69.3%) on hydroxychloroquine and 82 (30.7%) on non-hydroxychloroquine treatments. The average age was 46.0±13.3 years and 78.3% of the patients were males. Approximately 95.9% of the patients were symptomatic with mild (50.6%), moderate (32.6%), severe (8.2%), or ARDS symptoms (4.5%). Compared with no hydroxychloroquine, those on hydroxychloroquine had significantly longer length of stay (11.5±7.1 versus 7.8±4.3 days, p<0.001), more ICU admission (22.7% versus 9.8%, p=0.012), and more intubation (12.4% versus 3.7%, p=0.026). Improvement of symptoms (84.3% versus...
Introduction

Since its first appearance in Wuhan (China) in late 2019, more than 30 million patients globally were infected with severe acute respiratory syndrome coronavirus number 2 (SARS-CoV-2) with more than 950 thousands related deaths by mid-September 2020 [1, 2]. Although the mortality observed in the current coronavirus disease (COVID-19) pandemic (4.1% of closed cases) is much lower than other coronaviruses such as SARS-CoV (10%) and the Middle East Respiratory Syndrome-CoV (MERS-CoV, 35%)[3], the rapid and universal spread of COVID-19 caused unprecedented global public health emergency and major healthcare crises [4, 5].

With the lack of recognized therapeutic medications or effective vaccine, the management of COVID-19 was largely dependent on off-label use of available medications [6, 7]. Several medications have been tried during the pandemic including anti-viral drugs, antimalarial drugs, and immunomodulatory agents (such as tocilizumab and interferons) [6, 7].

Chloroquine and hydroxychloroquine have been used for decades in the prevention and treatment of malaria and then the treatment of some autoimmune diseases [8]. Their earlier use in the COVID pandemic was based on pre-pandemic reports that showed their ability to inhibit viral replication of several viruses including SARS and human immunodeficiency virus (HIV) [8, 9]. Additionally, in vitro reports published early in the pandemic showing the ability of hydroxychloroquine to inhibit SARS-CoV-2 replication [10]. The use of hydroxychloroquine in the COVID pandemic raised significant concerns as regards safety and efficacy, specially among cardiac patients [11]. Accumulating evidence and scientific debates forced several international organizations such as the World Health Organization (WHO) and the US Food and Drug Administration (FDA) to limit or halt the use of hydroxychloroquine in the management of patients with COVID-19 [11, 12]. The objective of the current study was to examine the effect of hydroxychloroquine on clinical improvement and mortality among patients with COVID-19 admitted earlier in the pandemic to general hospitals in Saudi Arabia.

Methods

Setting

The current study was conducted at four general hospitals at Western region, Saudi Arabia. The hospitals included 700-bed King Fahad General Hospital, 500-bed Alnoor Specialist Hospital, 300-bed East Jeddah Hospital, and 300-bed King Abdullah Medical Complex. All were located in Jeddah with exception of Alnoor Specialist Hospital which is located at Mecca. The hospitals were allowed to provide healthcare services for patients with COVID-19 in addition to other types of patients. The hospitals were following the guidelines of Saudi Ministry of Health (MOH) as regards testing, diagnosis, admission, isolation, management, and 81.7%, p=0.595) and hospitalization death (7.0% versus 1.2%, p=0.071) were not significantly different between groups. With exception of length of stay, the association of hydroxychloroquine with the above negative outcomes disappeared after adjustment for several factors including disease severity and concomitant use of azithromycin.

Conclusions: Hydroxychloroquine is not associated with better improvement of symptoms compared with other treatments. Moreover, it is associated with longer length of stay but not mortality or ICU admission in adjusted analysis.

Corresponding author: Mohammed Alghamdi, Infectious disease consultant, King Fahad General Hospital
Mobile: +966-555797611, Email: dr.mohd1391@yahoo.com

Received: Dec 07, 2020 Accepted: Dec 11, 2020 Published: Dec 14, 2020

Keywords: COVID-19, pandemic, hydroxychloroquine, efficacy, mortality, Saudi Arabia

Running title: Hydroxychloroquine in COVID-19 patients

Editor: Jose Luis Turabian, University of Madrid, Toledo, Spain.
discharge [13, 14].

**Design**

It was a prospective cohort study conducted between March 1, 2020 and May 30, 2020. The study design obtained all required ethical approvals from the Institutional Review Board (IRB) of the Saudi MOH. Informed consent was obtained from patients or their immediate family members after explaining the objectives of the study.

**Sample Size Calculation**

Assuming an improvement rate of 50% and assuming that hydroxychloroquine is used in the majority of patients, 240 patients (160 use hydroxychloroquine and 80 do not use hydroxychloroquine) would be required to detect 20% difference (60% versus 40%) in improvement using 80% power and 95% level of significance.

**Population**

The study targeted adult patients (age >18 years) with polymerase chain reaction (RT-PCR)-confirmed COVID-19 diagnosis admitted to any of the included four hospitals during the study duration. The patients were divided into two cohorts based on the status of hydroxychloroquine treatment, as per the Saudi MOH guidelines. Patients who had absolute or relative contraindication for using hydroxychloroquine were excluded from the study. These included known hypersensitivity to hydroxychloroquine or similar compounds, Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, decompensated heart failure, prolonged QTc interval, and preexisting retinopathy. Patients concomitantly receiving other medications including azithromycin, antivirals, and supportive treatment were not excluded.

**Recruitment and Data Collection**

Patients were conveniently recruited after obtaining informed consent. Structured study data collection sheet was used to collect the patient information. These included socio-demographic characteristics, exposure history, symptoms, comorbidity, chest imaging findings, relevant laboratory examinations, and outcomes.

**Outcome Definitions**

Clinical improvement was based on comparing the assessments of symptoms, disease severity, and chest imaging before and after the use of treatments. Disease severity was categorized into five groups; asymptomatic, mild (symptomatic without evidence of pneumonia or hypoxia), moderate (clinical signs of pneumonia but no hypoxia), severe (severe pneumonia or hypoxia), and acute respiratory distress syndrome (ARDS) [14, 15]. Other outcome measures included length of stay, need for intensive care unit (ICU) admission, need for intubation, need for inotropic support, and hospitalization death.

**Statistical Analysis**

Categorical variables were presented as frequencies and percentage while continuous variables were presented as means and standard deviations (SD) or median and inter-quartile range (IQR), as appropriate. Demographic, clinical, and outcome variables were compared between those who received and those who did not receive hydroxychloroquine. Chi-square or Fisher’s exact test, as appropriate, were used to examine differences in categorical variables while student t-test or Mann–Whitney test, as appropriate, were used to examine differences in continuous variables. To detect independent differences in outcome variables between those who received and those who did not receive hydroxychloroquine, multivariate logistic regression analysis models (for categorical outcomes) and general linear models (for length of stay) were run after adjusting for the variables that were significantly associated with hydroxychloroquine in univariate analysis. All P-values were two-tailed. P-value <0.05 was considered as significant. SPSS software (release 25.0, Armonk, NY: IBM Corp) was used for all statistical analyses.

**Results**

A total 267 patients have been included in the current analysis; 185 (69.3%) on hydroxychloroquine and 82 (30.7%) on non-hydroxychloroquine treatments. As shown in Table 1, the average age was 46.0±13.3 years and 78.3% of the patients were males. More than half (53.6%) of the patients were from Asian countries while Saudi patients represented less than a quarter (23.2%). One-fifth (19.5%) of the patients were currently employed and only 4.5% were healthcare
|                          | Hydroxychloroquine | Total       | P-value |
|--------------------------|--------------------|-------------|---------|
|                          | No                 | Yes         |         |
| **Age (years)**          |                    |             |         |
| Mean±SD                  | 44.0±14.0          | 47.0±12.8   | 0.093   |
| <35                      | 29 (35.8%)         | 33 (18.6%)  | 62 (24.0%) | 0.017 |
| 35-44                    | 15 (18.5%)         | 41 (23.2%)  | 56 (21.7%) |
| 45-54                    | 15 (18.5%)         | 53 (29.9%)  | 68 (26.4%) |
| ≥55                      | 22 (27.2%)         | 50 (28.2%)  | 72 (27.9%) |
| **Gender**               |                    |             |         |
| Male                     | 60 (73.2%)         | 149 (80.5%) | 209 (78.3%) | 0.178 |
| Female                   | 22 (26.8%)         | 36 (19.5%)  | 58 (21.7%) |
| **Nationality**          |                    |             |         |
| Saudi                    | 16 (19.5%)         | 46 (24.9%)  | 62 (23.2%) | 0.084 |
| Arab                     | 24 (29.3%)         | 32 (17.3%)  | 56 (21.0%) |
| Asia                     | 39 (47.6%)         | 104 (56.2%) | 143 (53.6%) |
| Others                   | 3 (3.7%)           | 3 (1.6%)    | 6 (2.2%) |
| **Employment**           |                    |             |         |
| Currently employed       | 20 (24.4%)         | 32 (17.3%)  | 52 (19.5%) | 0.002 |
| Not working              | 21 (25.6%)         | 31 (16.8%)  | 52 (19.5%) |
| Retired                  | 0 (0.0%)           | 2 (1.1%)    | 2 (0.7%) |
| Umrah                    | 6 (7.3%)           | 2 (1.1%)    | 8 (3.0%) |
| Unknown                  | 35 (42.7%)         | 118 (63.8%) | 153 (57.3%) |
| **Exposure**             |                    |             |         |
| Recent travel within 14 days of symptoms | 10 (12.2%) | 11 (5.9%) | 21 (7.9%) | 0.080 |
| Contact with patients with confirmed COVID-19 | 25 (30.5%) | 74 (40.0%) | 99 (37.1%) | 0.138 |
| **Other characteristics**|                    |             |         |
| Healthcare workers (HCWs) | 4 (4.9%)           | 8 (4.3%)    | 12 (4.5%) | >0.99 |
| Smoking                  | 9 (11.0%)          | 36 (19.5%)  | 45 (16.9%) | 0.088 |
| Pregnancy                | 2 (9.1%)           | 0 (0.0%)    | 2 (3.4%) | 0.140 |
Table 2. Clinical characteristics at admission among patients with confirmed COVID-19 by the treatment status

|                               | Hydroxychloroquine | Total          | P-value |
|-------------------------------|---------------------|----------------|---------|
|                               | No                  | Yes            |         |
| Comorbidity                   |                     |                |         |
| None                          | 54 (65.9%)          | 99 (53.5%)     | 153 (57.3%) | 0.081 |
| One                           | 17 (20.7%)          | 40 (21.6%)     | 57 (21.3%) |
| Two or more                   | 11 (13.4%)          | 46 (24.9%)     | 57 (21.3%) |
| Type of comorbidity           |                     |                |         |
| Hypertension                  | 14 (17.1%)          | 49 (26.5%)     | 63 (23.6%) | 0.095 |
| Diabetes                      | 16 (19.5%)          | 66 (35.7%)     | 82 (30.7%) | 0.008 |
| Chronic lung disease          | 0 (0.0%)            | 6 (3.2%)       | 6 (2.2%)  | 0.182 |
| Heart disease                 | 4 (4.9%)            | 9 (4.9%)       | 13 (4.9%) | >0.99 |
| Symptoms                      |                     |                |         |
| Asymptomatic                  | 9 (11.0%)           | 2 (1.1%)       | 11 (4.1%) | 0.001 |
| Symptomatic                   | 73 (89.0%)          | 183 (98.9%)    | 256 (95.9%) |
| Type of symptoms              |                     |                |         |
| Fever                         | 51 (62.2%)          | 123 (66.5%)    | 174 (65.2%) | 0.497 |
| Cough                         | 43 (52.4%)          | 144 (77.8%)    | 187 (70.0%) | <0.001 |
| Shortness of breath           | 13 (15.9%)          | 76 (41.1%)     | 89 (33.3%) | <0.001 |
| Chest pain                    | 2 (2.4%)            | 2 (1.1%)       | 4 (1.5%)  | 0.589 |
| Nausea or vomiting            | 8 (9.8%)            | 11 (5.9%)      | 19 (7.1%)  | 0.264 |
| Diarrhea                      | 6 (7.3%)            | 9 (4.9%)       | 15 (5.6%)  | 0.404 |
| Severity of symptoms          |                     |                |         |
| Asymptomatic                  | 9 (11.0%)           | 2 (1.1%)       | 11 (4.1%) | <0.001 |
| Mild                          | 50 (61.0%)          | 85 (45.9%)     | 135 (50.6%) |
| Moderate                      | 21 (25.6%)          | 66 (35.7%)     | 87 (32.6%) |
| Severe                        | 2 (2.4%)            | 20 (10.8%)     | 22 (8.2%)  |
| ARDS                          | 0 (0.0%)            | 12 (6.5%)      | 12 (4.5%)  |
| Chest imaging findings        |                     |                |         |
| Unremarkable                  | 49 (59.8%)          | 37 (20.1%)     | 86 (32.3%) | <0.001 |
| Findings detected             | 33 (40.2%)          | 147 (79.9%)    | 180 (67.7%) |
| Other related examinations    |                     |                |         |
| Systolic BP (mm Hg)           | 124.6±13.3          | 125.6±13.2     | 125.3±13.2 | 0.546 |
| Diastolic BP (mm Hg)          | 77.0±8.3            | 76.5±9.6       | 76.7±9.2  | 0.728 |
| Temperature (°C)              | 37.2±0.7            | 37.4±0.7       | 37.4±0.7  | 0.035 |
| Oxygen saturation at room air | 97.0±3.2            | 94.0±6.7       | 94.9±6.0  | <0.001 |
| Hemoglobin (g/dl)             | 13.6±2.3            | 12.7±2.1       | 13.0±2.2  | 0.009 |
| White blood cell count (x10 ^9/L) | 6.7±3.2            | 7.3±3.4       | 7.1±3.3  | 0.163 |
| Absolute lymphocyte count (x10 ^9/L) | 2.0±1.3            | 1.7±1.4       | 1.8±1.4  | 0.186 |
| Platelet count (x10 ^9/L)     | 248.7±124.3         | 251.0±112.3    | 250.3±115.8 | 0.884 |
| C-reactive protein (mg/dL)    | 1.6 (0.4-9.1)       | 7.5 (3.0-13.2) | 6.7 (1.5-11.8) | 0.001 |
| Creatinine (mg/dL)            | 0.9 (0.7-1.1)       | 0.9 (0.8-1.1)  | 0.9 (0.8-1.1) | 0.053 |
| D.dimer (mg/L)                | 0.6 (0.3-1.3)       | 0.9 (0.5-1.5)  | 0.8 (0.5-1.4) | 0.076 |
| Ferritin (ug/L)               | 311(102-668)        | 634(334-1159)  | 517(254-1031) | 0.001 |
| QTc duration (ms)             | 406.5±27.7          | 417.7±44.0     | 414.8±40.6 | 0.121 |

ARDS, acute respiratory distress syndrome
workers (HCWs). Approximately 16.9% of the patients were smokers and only 3.4% of the females were pregnant. Contact with patients with confirmed COVID-19 (37.1%) was much more common than recent travel within 14 days of symptoms (7.9%). Compared with no hydroxychloroquine, those who received hydroxychloroquine were more likely to be between 35 and 54 years and with unknown employment status.

Table 2 shows the clinical characteristics of the patients at admission. Approximately 42.7% of the patients had one or more comorbid disease, specially diabetes (30.7%) and hypertension (23.6%). The majority (95.9%) of the patients were symptomatic; with mainly cough (70.0%), fever (65.2%), and shortness of breath (33.3%). The severity ranged between mild (50.6%), moderate (32.6%), severe (8.2%), or ARDS symptoms (4.5%). Approximately two-thirds (67.7%) of chest imaging were abnormal (mainly opacities and consolidations). The average temperature was 37.4±0.7 °C, oxygen saturation was 94.9%±6.0% at room air, and QTc duration was 414.8±40.6. Median C-reactive protein (CRP) was 6.7 (1.5-11.8) mg/dl and ferritin was 517 (254-1031) ug/L. Compared with no hydroxychloroquine, those who received hydroxychloroquine were more likely to be symptomatic and have cough, shortness of breath, severer form of disease, diabetes, abnormal chest imaging, higher temperature, lower oxygen saturation at room air, lower hemoglobin, higher CRP, and higher ferritin at admission.

Irrespective of hydroxychloroquine, patients included in the study were receiving azithromycin (73.0%), supportive treatment (48.7%), antivirals (17.6%), and zinc (9.0%). Table 3 shows the clinical characteristics of the patients after receiving hydroxychloroquine or non-hydroxychloroquine treatments. Approximately 58.8% of the patients were still symptomatic. Approximately 10.9% of the patients still had severe disease or ARDS. Approximately 60.0% of chest imaging was still abnormal. The average temperature slightly decreased to 37.1±0.4 °C and oxygen saturation slightly increased to 96.5%±3.3% at room air. Compared with no hydroxychloroquine, those who received hydroxychloroquine were more likely to use azithromycin, still symptomatic with more fever, cough, and shortness of breath, have severer form of disease, abnormal chest imaging, lower levels of oxygen saturation at room air and hemoglobin, and higher levels of white blood cell (WBC) count, platelet count, creatinine, D-dimer, and ferritin after receiving hydroxychloroquine.

As shown in Table 4, patients experienced clinical improvement mainly in symptoms (83.5%), disease severity (47.9%), and to less extent chest imaging (10.6%) after receiving hydroxychloroquine or non-hydroxychloroquine treatments. The average length of stay was 10.4±6.6 days. Approximately 18.7% of the patients required ICU admission, 9.7% required intubation, 2.6% required inotropic support, and 5.2% died during admission. Compared with no hydroxychloroquine, those on hydroxychloroquine had significantly longer length of stay (11.5±7.1 versus 7.8±4.3 days, p<0.001), more ICU admission (22.7% versus 9.8%, p=0.012), and more intubation (12.4% versus 3.7%, p=0.026). The difference in ICU admission and intubation but not length of stay disappeared after stratification by disease severity and to less extent by the presence of comorbidity (data not shown).

Table 5 shows the results of multivariate analysis of study outcomes. With two exceptions, patients who received hydroxychloroquine had generally similar outcomes compared with those who received non-hydroxychloroquine treatments after adjusting for several factors that were significantly different between the two groups in univariate analysis (Tables 1 through 4). Nevertheless, the length of stay was significantly longer (9.8±2.4 versus 7.6±2.0, p=0.006) and the improvement in chest imaging was significantly lower (odds ratio was 0.02, 95% CI 0.001-0.20, p=0.001) among patients who received hydroxychloroquine compared with those who received non-hydroxychloroquine treatments.

Discussion
The current study examined the efficacy and safety of hydroxychloroquine among admitted patients with COVID-19 of different disease severity. The findings showed that hydroxychloroquine was the second most commonly used single medication (69.3%) after azithromycin (73.0%). It was used approximately four-folds higher than all antiviral medications. The heavy use of hydroxychloroquine is probably reflecting...
Table 3. Clinical characteristics after using hydroxychloroquine among patients with confirmed COVID-19 by the treatment status

|                                               | Hydroxychloroquine | Total     | P-value |
|------------------------------------------------|--------------------|-----------|---------|
| **Other medication**                          |                    |           |         |
| Azithromycin                                   | 45 (54.9%)         | 150 (81.1%) | 195 (73.0%) | <0.001 |
| Lopinavir/ritonavir (Kaletra)                  | 16 (19.5%)         | 27 (14.6%) | 43 (16.1%) | 0.313  |
| Oseltamivir (Tamiflu)                          | 2 (2.4%)           | 2 (1.1%)  | 4 (1.5%)  | 0.589  |
| Zinc                                           | 8 (9.8%)           | 16 (8.6%) | 24 (9.0%) | 0.770  |
| Supportive treatment                           | 45 (54.9%)         | 85 (45.9%) | 130 (48.7%) | 0.178  |
| **Symptoms**                                   |                    |           |         |
| Asymptomatic                                   | 43 (52.4%)         | 67 (36.2%) | 110 (41.2%) | 0.013  |
| Symptomatic                                    | 39 (47.6%)         | 118 (63.8%) | 157 (58.8%) |
| **Type of symptoms**                           |                    |           |         |
| Fever                                          | 1 (1.2%)           | 17 (9.2%) | 18 (6.7%) | 0.017  |
| Cough                                          | 3 (3.7%)           | 32 (17.3%) | 35 (13.1%) | 0.002  |
| Shortness of breath                            | 4 (4.9%)           | 32 (17.3%) | 36 (13.5%) | 0.006  |
| Nausea or vomiting                             | 0 (0.0%)           | 1 (0.5%)  | 1 (0.4%)  | >0.99  |
| Diarrhea                                       | 0 (0.0%)           | 2 (1.1%)  | 2 (0.7%)  | >0.99  |
| **Severity of symptoms**                       |                    |           |         |
| Asymptomatic                                   | 43 (52.4%)         | 67 (36.2%) | 110 (41.2%) | 0.033  |
| Mild                                           | 29 (35.4%)         | 69 (37.3%) | 98 (36.7%) |
| Moderate                                       | 7 (8.5%)           | 23 (12.4%) | 30 (11.2%) |
| Severe                                         | 2 (2.4%)           | 10 (5.4%) | 12 (4.5%) |
| ARDS                                           | 1 (1.2%)           | 16 (8.6%) | 17 (6.4%) |
| **Chest imaging findings**                     |                    |           |         |
| Unremarkable                                   | 39 (79.6%)         | 33 (25.2%) | 72 (40.0%) | <0.001 |
| Findings detected                              | 10 (20.3%)         | 98 (74.8%) | 108 (60.0%) |
| **Other related examinations**                 |                    |           |         |
| Systolic BP (mm Hg)                            | 121.9±7.6          | 121.2±8.8 | 121.4±8.5 | 0.595  |
| Diastolic BP (mm Hg)                           | 75.1±7.6           | 74.9±8.8 | 74.9±8.5 | 0.863  |
| Temperature (°C)                               | 37.0±0.3           | 37.1±0.5 | 37.1±0.4 | 0.144  |
| Oxygen saturation at room air (%)              | 97.5±2.4           | 96.1±3.5 | 96.5±3.3 | 0.010  |
| Hemoglobin (g/dl)                              | 13.6±2.3           | 12.7±2.1 | 13.0±2.2 | 0.009  |
| White blood cell count (x10 ^9/L)              | 6.7±3.4            | 8.7±5.6 | 8.1±5.1 | 0.011  |
| Absolute lymphocyte count (x10 ^9/L)           | 2.4±1.7            | 2.1±1.8 | 2.2±1.8 | 0.478  |
| Platelet count (x10 ^9/L)                      | 288.1±150.8        | 354.4±149.9 | 335.0±152.8 | 0.005  |
| C-reactive protein (CRP, mg/dL)                | 2.5 (0.9-11.9)     | 6.2 (2.4-11.8) | 5.3 (1.5-11.6) | 0.118  |
| Creatinine (mg/dL)                             | 0.8 (0.7-1.0)      | 0.9 (0.8-1.1) | 0.9 (0.7-1.1) | 0.018  |
| D.dimer (mg/L)                                 | 0.8 (0.2-1.2)      | 1.2 (0.7-4.3) | 1.0 (0.6-3.1) | 0.018  |
| Ferritin (ug/L)                                | 346(178-769)       | 771(370-1248) | 691(301-1140) | 0.021  |

ARDS, acute respiratory distress syndrome
Table 4. Study outcomes among patients with confirmed COVID-19 by treatment status

| Parameter                        | Hydroxychloroquine | Total       | P-value |
|----------------------------------|---------------------|-------------|---------|
|                                 | No                  | Yes         |         |
| Improved symptoms                | 67 (81.7%)          | 156 (84.3%) | 223 (83.5%) | 0.595 |
| Reduced severity                 | 42 (51.2%)          | 86 (46.5%)  | 128 (47.9%) | 0.475 |
| Improved chest imaging           | 8 (16.3%)           | 11 (8.5%)   | 19 (10.6%)  | 0.128 |
| Length of stay (days)            | 7.8±4.3             | 11.5±7.1    | 10.4±6.6 | <0.001 |
| Length of stay (days)            | 7 (5-9)             | 10 (7-14)   | 9 (6-13)   | <0.001 |
| ICU admission                    | 8 (9.8%)            | 42 (22.7%)  | 50 (18.7%)  | 0.012 |
| Intubation                       | 3 (3.7%)            | 23 (12.4%)  | 26 (9.7%)  | 0.026 |
| Inotropic support                | 0 (0.0%)            | 7 (3.8%)    | 7 (2.6%)   | 0.104 |
| Death                            | 1 (1.2%)            | 13 (7.0%)   | 14 (5.2%)  | 0.071 |

Table 5. Adjusted outcomes* (multivariate analysis) among patients with confirmed COVID-19 who received hydroxychloroquine compared with those who received non-hydroxychloroquine treatments

| Parameter                        | Odds ratio (OR) | 95% confidence interval of OR | P-value | Adjusted R-square |
|----------------------------------|-----------------|-----------------------------|---------|-------------------|
|                                  |                 | Lower | Upper            |         |                   |
| Improved symptoms                | 1.14            | 0.42  | 3.10             | 0.797   | 0.280             |
| Reduced severity                 | 0.58            | 0.27  | 1.21             | 0.146   | 0.305             |
| Improved chest imaging           | 0.02            | 0.001 | 0.20             | 0.001   | 0.499             |
| ICU admission                    | 1.02            | 0.39  | 2.69             | 0.967   | 0.215             |
| Intubation                       | 1.76            | 0.37  | 8.49             | 0.480   | 0.351             |
| Inotropic support                | >10             | 0.00  |                 | 0.996   | 0.325             |
| Death                            | 1.04            | 0.07  | 15.66            | 0.978   | 0.575             |
| Length of stay (days)            |                 |       |                  |         |                   |
| Hydroxychloroquine               |                 |       |                  |         |                   |
| No                               | 7.6±2.0         | 9.8±2.4 | 8.6±2.5 | 0.006 |
| Yes                              |                 |       |                  |         |                   |

* Adjusted for age, employment status, diabetes, symptoms (cough and shortness of breath), temperature, severity of disease, oxygen saturation at room air, chest imaging findings, use of azithromycin, and levels of hemoglobin and creatinine.
the MOH guidelines at the time of study (March through May) which placed hydroxychloroquine as a first-line drug for all patients (mild to ARDS) while adding antivirals for severe and critical patients [14]. The high use of hydroxychloroquine underscores the importance of reviewing local efficacy and safety data.

The patients in the current study experienced a significant clinical improvement specially in symptoms and disease severity after treatment. However, hydroxychloroquine was not associated with better clinical improvement (including symptoms and severity) than non-hydroxychloroquine treatments in both univariate and multivariate analysis. On the other hand, improvement of chest imaging was significantly slower among those receiving hydroxychloroquine. Consistent with current findings, meta-analysis studies could not detect significant clinical improvement (mainly symptoms) in patients receiving hydroxychloroquine [16-18]. However, the results of these studies were conflicting as regards the ability of hydroxychloroquine to limit the radiologic progression [17-19]. Variability may be related to the difference in disease severity and time of re-assessment of chest imaging in different study designs.

Hydroxychloroquine in the current study was associated with longer length of stay in both univariate and multivariate analysis. Similarly, hydroxychloroquine with or without azithromycin was associated with longer length of stay in both univariate and multivariate analysis in a retrospective cohort design [20]. However, most of the previous studies either did not focus on the length of stay as an outcome or could not find benefit of hydroxychloroquine on the length of stay [21, 22]. It should be mentioned that the length of stay may be easily affected by the hospital capacity and discharge polices [20].

The patients in the current study who were receiving hydroxychloroquine experienced negative outcomes including ICU admission and intubation, which largely disappeared in multivariate analysis adjusted for several factors including disease severity and concomitant use of azithromycin. This finding may indicate that the above negative outcomes were not caused by hydroxychloroquine itself but rather by the difference between treatment groups as regards clinical picture, severity, and other received treatments. Similarly, previous studies could not detect any significant increase in ICU admission or intubation in patients receiving hydroxychloroquine [19, 21, 23].

The current study showed that hydroxychloroquine was associated with an insignificant increase in mortality that completely disappeared in multivariate analysis. Previous studies examining the impact of hydroxychloroquine on all-cause mortality were conflicting and probably changing overtime. For example, earlier meta-analysis reports that included few studies published before the end of April 2020 showed a significant increase in mortality among patients receiving hydroxychloroquine, with risk ratios above two [19, 24]. However, the majority of include studies were observation with high level of heterogeneity due to variable doses, disease severity, and concomitant treatments. Later meta-analysis reports that included more recent studies published up to June or July 2020 found no significant increase in mortality among patients receiving hydroxychloroquine [16, 17, 25, 26]. A recent local prospective cohort study (pre-review publication) showed that hydroxychloroquine was associated with lower hospital admission and mortality among outpatients with mild-moderate COVID-19 symptoms [27]. The apparently conflicting finding may underscore the variability of the outcome by the type of patient and severity of the disease. Interestingly, a two recent report showed a significant increase in mortality only among patients who were receiving both hydroxychloroquine and azithromycin [25, 26]. Consistently, a sub-analysis of the current data showed that this group had the worst outcome in univariate analysis, probably because physicians were reserving hydroxychloroquine/azithromycin combination for severe/critical patients (data not shown). Additionally, adjustment for concomitant azithromycin use was a major factor that pushed the adjusted odds ratio for mortality towards null.

The current study is considered the first study in Saudi Arabia to comprehensively examine the efficacy and safety of hydroxychloroquine in admitted patients. The study used a prospective multi-hospital design, included patients with different severity, and reported both univariate and multivariate analysis. Nevertheless, we acknowledge a number of limitations. The lack of randomization may have introduced selection bias.
However, the observational design allowed for evaluation of actual treatment practices while adjusting for group differences at admission in multivariate analysis. The concomitant use of other types of treatments represented an important confounding factor for the current outcomes. However, it is probably unethical to deprive patients from other potential treatments at the time of pandemic with limited therapeutic information. Additionally, this has been adjusted for in multivariate analysis.

In conclusion, hydroxychloroquine have been heavily used to treat patients with COVID-19 admitted to general hospitals in Saudi Arabia during the time of the study. Hydroxychloroquine was not associated with better clinical improvement and it was associated with longer length of stay. The observed univariate associations between hydroxychloroquine and negative outcomes such as ICU admission, intubation, and mortality can be largely explained by the differences between treatment groups in clinical severity and other received treatments. The current findings represent a significant addition to the debate about hydroxychloroquine use in COVID-19 pandemic.

Acknowledgments:
Thanks for all staff at four hospitals who assisted in data collection and other study logistics

Funding
None received

Disclosures
The authors report no conflicts of interest in this work

Statement
All authors have been acknowledged as contributors of submitted work and fulfill the standard criteria for authorship. All authors have read and approved the submission of the current version of the manuscript. The material included in this manuscript is original and it has been neither published elsewhere nor submitted for publication simultaneously.

References
1. World Health Organization: WHO Coronavirus Disease (COVID-19) Dashboard. Situation by Country, Territory & Area. URL: https://covid19.who.int/table (Last accessed September 15, 2020). 2020.
2. Worldometer: Worldometer’s Covid-19 pandemic data. URL: https://www.worldometers.info/coronavirus/ (Last accessed September 15, 2020).
3. Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS: Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Infez Med 2020, 28(suppl 1):6-17.
4. Kumar A, Nayar KR: COVID-19 and Mass Fatality Management: A Public Health Challenge. Disaster Med Public Health Prep 2020:1-2.
5. Hamid H, Abid Z, Amir A, Rehman TU, Akram W, Mehboob T: Current burden on healthcare systems in low- and middle-income countries: recommendations for emergency care of COVID-19. Drugs Ther Perspect 2020:1-3.
6. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A: Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med 2020, 38(7):1488-1493.
7. Lam S, Lombardi A, Ouanounou A: COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol 2020, 886:173451.
8. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R: Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003, 3(11):722-727.
9. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005, 2: 69.
10. Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, Bukhari A, Alfaleh MA, Memish ZA: Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Med Infect Dis 2020, 35:101735.
11. Stevenson A, Kirresh A, Conway S, White L, Ahmad M, Little C: Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified? Open Heart 2020, 7(2).
12. Cortegiani A, Ippolito M, Ingoglia G, Iozzo P,
Giarratano A, Einav S: Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. *J Crit Care* 2020, 59:176-190.

13. Saudi Ministry of Health: COVID-19 Coronavirus Disease Guidelines. Version 1.3, May 2020. URL: https://covid19.cdc.gov.sa/wp-content/uploads/2020/05/COVID-19-Coronavirus-Disease-Guidelines-en.pdf (Last accessed September 15, 2020).

14. Saudi Ministry of Health: MOH Protocol for Patients Suspected of/Confirmed with COVID-19. Version 1.4, April 12, 2020. URL: http://omranhospital.net/wp-content/uploads/2020/05/MoH-COVID-19-Protocol-V1.463931.pdf-1.pdf (Last accessed September 15, 2020).

15. World Health Organization: Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. URL: https://apps.who.int/iris/handle/10665/331446 (Last accessed September 15, 2020).

16. Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K, Nischal N, Soneja M, Sharma A, Maulik SK, Shelimar et al: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. *J Gen Intern Med* 2020.

17. Elsawah HK, Elsokary MA, Elrazzaz MG, ElShafey AH: Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials. *J Med Virol* 2020.

18. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, Prajapat M, Shekhar N, Kumar S, Singh R et al: Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. *J Med Virol* 2020, 92(7):776-785.

19. Ullah W, H MA, Roomi S, Sattar Y, Almas T, Narayana Gowda S, Saeed R, Mukhtar M, Ahmad A, Oliver T et al: Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. *J Clin Med Res* 2020, 12 (8):483-491.

20. Albani F, Fusina F, Giovannini A, Ferretti P, Granato A, Prezioso C, Divizia D, Sabaini A, Marri M, Malpetti E et al: Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19. *J Clin Med* 2020, 9(9).

21. Karolyi M, Pawelka E, Mader T, Omid S, Kelani H, Ely S, Jilma B, Baumgartner S, Laferl H, Ott C et al: Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort. *Wien Klin Wochenschr* 2020.

22. Kalligeros M, Shehadeh F, Atalla E, Miyonka EK, Aung S, Pandita A, Larkin J, Sanchez M, Touzard-Romo F, Brotherton A et al: Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study. *J Glob Antimicrob Resist* 2020, 22:842-844.

23. Abd-Elsalam S, Emsal ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, Ahmed OA, Soliman S, Serangawy GN, Alborae M: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. *Am J Trop Med Hyg* 2020.

24. Singh AK, Singh A, Singh R, Misra A: "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.". *Diabetes Metab Syndr* 2020, 14(4):589-596.

25. Fiolet T, Guihur A, Rebeaud M, Mulot M, Peiffer-Smaja N, Mahamat-Saleh Y: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis. *Clin Microbiol Infect* 2020.

26. Das RR, Jaiswal N, Dev N, Naik SS, Sankar J: Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)* 2020, 7:482.

27. Sulaiman T, Mohana A, Alawdah L, Mahmoud N, Hassanein M, Wani T, Alfaifi A, Alenazi E, Radwan N, Al Khalifah N et al: The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study. *medRxiv* 2020:2020.2009.2009.20184143.